Corxel Pharmaceuticals Raises $287M Series D1 to Advance Oral GLP-1 Obesity Drug CX11

Corxel Pharmaceuticals announced on January 22, 2026, a $287 million Series D1 funding round to advance its cardiometabolic pipeline, including the oral GLP-1 receptor agonist CX11.1 2 3

CX11 is in Phase 2 trials in the U.S. for obesity and overweight patients by Corxel, and Phase 3 in China by Vincentage, with plans for global Phase 2 in Type 2 Diabetes and Phase 3 preparations.1 2 3

New investors include SR One, TCGX, RA Capital Management, HBM Healthcare Investments, SymBiosis, Adage Capital Management, Invus, and SilverArc Capital; existing investors RTW Investments and Hengdian Group Capital also participated.2 3

Funds will support CX11 development, other programs like JX10 for acute ischemic stroke and JX09 for hypertension, and global operations.2 3

Corxel, with offices in New Jersey, Hong Kong, Shanghai, and Beijing, licensed CX11 from Chinese drugmaker Vincentage in 2024.1 3

Sources:

1. https://www.biopharmadive.com/news/corxel-oral-glp1-vincentage-series-d-china-deal/810242/

2. https://www.globenewswire.com/news-release/2026/01/22/3223696/0/en/CORXEL-Announces-287-million-Series-D1-Financing-to-Further-Advance-Its-Cardiometabolic-Pipeline-including-Oral-Small-Molecule-GLP-1-Receptor-Agonist.html

3. https://www.biospace.com/business/chinas-corxel-nabs-287m-series-d1-to-bankroll-glp-1-pill

Sources:

Leave a Reply Cancel reply